Symbols / ENVB
ENVB Chart
About
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.06M |
| Enterprise Value | -2.44M | Income | -11.25M | Sales | — |
| Book/sh | 6.67 | Cash/sh | 6.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | 0.00 | Forward P/E | -1.56 | PEG | — |
| P/S | — | P/B | 0.33 | P/C | — |
| EV/EBITDA | 0.26 | EV/Sales | — | Quick Ratio | 4.15 |
| Current Ratio | 4.60 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 1390.68 | EPS next Y | -1.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-28 17:00 | ROA | -133.22% |
| ROE | -262.78% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.39M |
| Shs Float | 515.46K | Short Float | 5.59% | Short Ratio | 1.24 |
| Short Interest | — | 52W High | 54.00 | 52W Low | 1.96 |
| Beta | 0.28 | Avg Volume | 1.03M | Volume | 118.20K |
| Target Price | — | Recom | None | Prev Close | $2.06 |
| Price | $2.20 | Change | 6.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.37
Latest analyst target
3. DCF / Fair value
$-50.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.37
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-01-30 | init | HC Wainwright & Co. | — → Buy | $10 |
- AbbVie's $1.2B depression drug linked to Enveric patent as petition withdrawn - Stock Titan Wed, 25 Feb 2026 13
- Why Did IXHL Stock Tank Over 32% Today? - Stocktwits Wed, 25 Feb 2026 14
- Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Asianet Newsable Wed, 25 Feb 2026 15
- Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Benzinga Wed, 25 Feb 2026 13
- Enveric Biosciences (ENVB) Price Target Increased by 1,100.00% to 122.40 - Nasdaq Wed, 29 Oct 2025 07
- Enveric Biosciences stock soars after revealing new data on lead drug candidate - Investing.com Nigeria hu, 19 Feb 2026 14
- New Enveric data supports non-hallucinogenic depression and anxiety strategy - Stock Titan hu, 19 Feb 2026 13
- Enveric Biosciences Announces Reverse Stock Split - Business Wire hu, 23 Oct 2025 07
- Enveric Biosciences (ENVB) Stock Surges on Patent Win: News, Forecast & Analysis as of December 10, 2025 - TechStock² Wed, 10 Dec 2025 08
- Morning Market Movers: ASPC, ENVB, AFJK, JXG See Big Swings - RTTNews Wed, 10 Dec 2025 08
- Why Did ENVB Stock More Than Double In Value Today? - Stocktwits Wed, 10 Dec 2025 08
- Enveric's EB-003 Assay Data Shows Dual 5-HTA Pathway Engagement; Stock Up - Nasdaq hu, 19 Feb 2026 15
- Enveric Biosciences stock soars after receiving patent allowance By Investing.com - Investing.com Nigeria Wed, 10 Dec 2025 08
- Enveric Biosciences (NASDAQ: ENVB) receives USPTO Notice of Allowance for EVM301 - Stock Titan ue, 09 Dec 2025 08
- Why Is ENVB Stock Rising Today? - Stocktwits Mon, 29 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7633 | — | — | Stock Award(Grant) at price 0.00 per share. | WEBB MICHAEL D | Director | — | 2025-12-23 00:00:00 | D |
| 1 | 7633 | — | — | Stock Award(Grant) at price 0.00 per share. | PASQUALONE FRANK | Director | — | 2025-12-23 00:00:00 | D |
| 2 | 7633 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHABACKER MARCUS | Director | — | 2025-12-23 00:00:00 | D |
| 3 | 7633 | — | — | Stock Award(Grant) at price 0.00 per share. | KEGLER GEORGE A. JR | Director | — | 2025-12-23 00:00:00 | D |
| 4 | 60296 | — | — | Stock Award(Grant) at price 0.00 per share. | TUCKER JOSEPH EDWARD | Chief Executive Officer | — | 2025-12-23 00:00:00 | D |
| 5 | 40198 | — | — | Stock Award(Grant) at price 0.00 per share. | COVENEY KEVIN MICHAEL | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 6 | 7633 | — | — | Stock Award(Grant) at price 0.00 per share. | DEWITT SHEILA | Director | — | 2025-12-23 00:00:00 | D |
| 7 | 98866 | nan | — | — | TUCKER JOSEPH EDWARD | Chief Executive Officer | — | 2025-05-08 00:00:00 | D |
| 8 | 24717 | nan | — | — | FACCHINI PETER JAMES | Chief Technology Officer | — | 2025-05-08 00:00:00 | D |
| 9 | 74150 | nan | — | — | COVENEY KEVIN MICHAEL | Chief Financial Officer | — | 2025-05-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 9.66K | 216.33K | 692.49 | -3.90M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.07 | 0.13 |
| NormalizedEBITDA | -9.34M | -18.92M | -19.53M | -26.39M |
| TotalUnusualItems | 45.99K | 1.03M | 9.30K | -29.35M |
| TotalUnusualItemsExcludingGoodwill | 45.99K | 1.03M | 9.30K | -29.35M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.57M | -17.31M | -18.50M | -48.98M |
| ReconciledDepreciation | 337.49K | 408.03K | 435.20K | 681.61K |
| EBITDA | -9.29M | -17.89M | -19.52M | -55.74M |
| EBIT | -9.63M | -18.30M | -19.95M | -56.42M |
| NetInterestIncome | 219.00 | 3.71K | -5.25K | -10.32K |
| InterestExpense | 5.25K | 10.32K | ||
| InterestIncome | 219.00 | 3.71K | ||
| NormalizedIncome | -9.61M | -18.12M | -18.51M | -23.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.57M | -17.31M | -18.50M | -48.98M |
| TotalExpenses | 9.63M | 18.30M | 19.96M | 27.07M |
| RentExpenseSupplemental | 0.00 | 1.85M | 0.00 | 1.13M |
| TotalOperatingIncomeAsReported | -9.63M | -16.45M | -27.42M | -64.62M |
| DilutedAverageShares | 502.90K | 143.94K | 96.40K | 31.49K |
| BasicAverageShares | 502.90K | 143.94K | 96.40K | 31.49K |
| DilutedEPS | -19.04 | -1.46K | -195.00 | -18.66K |
| BasicEPS | -19.04 | -1.46K | -195.00 | -18.66K |
| DilutedNIAvailtoComStockholders | -9.57M | -17.46M | -18.80M | -48.98M |
| NetIncomeCommonStockholders | -9.57M | -17.46M | -18.80M | -48.98M |
| PreferredStockDividends | 147.99K | 295.98K | ||
| NetIncome | -9.57M | -17.31M | -18.50M | -48.98M |
| MinorityInterests | 0.00 | -19.04K | -33.01K | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -9.57M | -17.29M | -18.47M | -48.98M |
| NetIncomeContinuousOperations | -9.57M | -17.29M | -18.47M | -48.98M |
| TaxProvision | 8.93K | 28.91K | -1.49M | -7.45M |
| PretaxIncome | -9.57M | -17.26M | -19.96M | -56.43M |
| OtherIncomeExpense | 65.99K | 1.03M | 9.30K | -29.35M |
| OtherNonOperatingIncomeExpenses | 20.00K | -1.13M | ||
| SpecialIncomeCharges | 0.00 | -7.45M | -38.68M | |
| ImpairmentOfCapitalAssets | 0.00 | 7.45M | 38.68M | |
| GainOnSaleOfSecurity | 45.99K | 1.03M | 7.46M | 9.33M |
| NetNonOperatingInterestIncomeExpense | 219.00 | 3.71K | -5.25K | -10.32K |
| InterestExpenseNonOperating | 5.25K | 10.32K | ||
| InterestIncomeNonOperating | 219.00 | 3.71K | ||
| OperatingIncome | -9.63M | -18.30M | -19.96M | -27.07M |
| OperatingExpense | 9.63M | 18.30M | 19.96M | 27.07M |
| DepreciationAmortizationDepletionIncomeStatement | 337.49K | 343.98K | 327.91K | 656.64K |
| DepreciationAndAmortizationInIncomeStatement | 337.49K | 343.98K | 327.91K | 656.64K |
| ResearchAndDevelopment | 2.84M | 7.25M | 8.03M | 4.79M |
| SellingGeneralAndAdministration | 6.45M | 10.70M | 11.61M | 21.62M |
| GeneralAndAdministrativeExpense | 6.45M | 10.70M | 11.61M | 21.62M |
| OtherGandA | 6.45M | 8.85M | 11.61M | 20.50M |
| RentAndLandingFees | 0.00 | 1.85M | 0.00 | 1.13M |
| GrossProfit | 0.00 | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 678.00K | 182.62K | 138.55K | 43.44K |
| ShareIssued | 678.00K | 182.62K | 138.55K | 43.44K |
| TotalDebt | 0.00 | 63.82K | 176.30K | |
| TangibleBookValue | 1.55M | 1.75M | 14.29M | 13.79M |
| InvestedCapital | 1.59M | 1.96M | 14.67M | 22.31M |
| WorkingCapital | 1.24M | 1.24M | 14.44M | 15.00M |
| NetTangibleAssets | 1.55M | 1.75M | 14.29M | 13.79M |
| CapitalLeaseObligations | 0.00 | 63.82K | 176.30K | |
| CommonStockEquity | 1.59M | 1.96M | 14.67M | 22.31M |
| TotalCapitalization | 1.59M | 1.96M | 14.67M | 22.31M |
| TotalEquityGrossMinorityInterest | 1.59M | 1.96M | 15.56M | 22.31M |
| MinorityInterest | 0.00 | 0.00 | 885.03K | 0.00 |
| StockholdersEquity | 1.59M | 1.96M | 14.67M | 22.31M |
| OtherEquityInterest | -1.82M | |||
| GainsLossesNotAffectingRetainedEarnings | -594.52K | -569.75K | -536.73K | -30.80K |
| OtherEquityAdjustments | -594.52K | -569.75K | -536.73K | -30.80K |
| RetainedEarnings | -106.07M | -96.50M | -79.21M | -60.74M |
| AdditionalPaidInCapital | 108.26M | 100.84M | 94.40M | 83.07M |
| CapitalStock | 6.78K | 1.83K | 20.78K | 6.52K |
| CommonStock | 6.78K | 1.83K | 20.78K | 6.52K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.49M | 2.34M | 4.00M | 4.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 1.68M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 | 0.00 |
| DerivativeProductLiabilities | 653.67K | |||
| NonCurrentDeferredLiabilities | 0.00 | 1.61M | ||
| NonCurrentDeferredTaxesLiabilities | 0.00 | 1.61M | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 68.86K | ||
| LongTermCapitalLeaseObligation | 0.00 | 68.86K | ||
| CurrentLiabilities | 1.49M | 2.34M | 4.00M | 2.74M |
| OtherCurrentLiabilities | 3.09K | 49.08K | 1.76M | 653.67K |
| CurrentDebtAndCapitalLeaseObligation | 63.82K | 107.44K | ||
| CurrentCapitalLeaseObligation | 0.00 | 63.82K | 107.44K | |
| PayablesAndAccruedExpenses | 1.49M | 2.29M | 2.17M | 1.98M |
| CurrentAccruedExpenses | 455.72K | 1.05M | 1.71M | 1.29M |
| Payables | 1.03M | 1.24M | 463.27K | 683.39K |
| OtherPayable | 15.19K | |||
| DuetoRelatedPartiesCurrent | 232.89K | 0.00 | ||
| TotalTaxPayable | 261.10K | 22.32K | 0.00 | |
| AccountsPayable | 521.75K | 1.22M | 463.27K | 683.39K |
| TotalAssets | 3.08M | 4.30M | 19.55M | 26.72M |
| TotalNonCurrentAssets | 347.96K | 718.31K | 1.12M | 8.98M |
| GoodwillAndOtherIntangibleAssets | 42.18K | 210.93K | 379.69K | 8.51M |
| OtherIntangibleAssets | 379.69K | 6.92M | ||
| Goodwill | 0.00 | 1.59M | ||
| NetPPE | 305.78K | 507.38K | 741.30K | 470.73K |
| AccumulatedDepreciation | -489.40K | -357.71K | -178.78K | -27.34K |
| GrossPPE | 795.18K | 865.09K | 920.08K | 498.08K |
| OtherProperties | 769.11K | 836.71K | 894.94K | 487.26K |
| MachineryFurnitureEquipment | 26.07K | 28.38K | 25.14K | 10.82K |
| CurrentAssets | 2.73M | 3.58M | 18.43M | 17.74M |
| OtherCurrentAssets | 708.05K | 380.84K | ||
| CurrentDeferredAssets | 0.00 | 567.60K | 0.00 | |
| PrepaidAssets | 493.56K | 501.34K | 708.05K | 380.84K |
| Receivables | 0.00 | 224.61K | 0.00 | |
| TaxesReceivable | 0.00 | 224.61K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 2.24M | 2.29M | 17.72M | 17.36M |
| CashAndCashEquivalents | 2.24M | 2.29M | 17.72M | 17.36M |
| CashFinancial | 2.24M | 2.29M | 17.72M | 17.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.73M | -14.10M | -17.73M | -12.32M |
| RepurchaseOfCapitalStock | 0.00 | -1.05M | 0.00 | |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 3.37M | 0.00 | 17.22M | 21.61M |
| CapitalExpenditure | -5.18K | -584.16K | -864.72K | |
| InterestPaidSupplementalData | 0.00 | 0.00 | 5.25K | 10.32K |
| IncomeTaxPaidSupplementalData | 5.00K | 9.51K | 0.00 | 0.00 |
| EndCashPosition | 2.24M | 2.29M | 17.72M | 17.36M |
| BeginningCashPosition | 2.29M | 17.72M | 17.36M | 1.58M |
| EffectOfExchangeRateChanges | 5.35K | -10.02K | -81.36K | 144.94K |
| ChangesInCash | -52.30K | -15.43M | 449.25K | 15.63M |
| FinancingCashFlow | 7.67M | -1.34M | 18.18M | 24.90M |
| CashFlowFromContinuingFinancingActivities | 7.67M | -1.34M | 18.18M | 24.90M |
| NetOtherFinancingCharges | -181.86K | -291.08K | 958.04K | |
| ProceedsFromStockOptionExercised | 4.48M | 0.00 | 0.00 | 3.29M |
| NetPreferredStockIssuance | 0.00 | -1.05M | 0.00 | |
| PreferredStockPayments | 0.00 | -1.05M | 0.00 | |
| NetCommonStockIssuance | 3.37M | 0.00 | 17.22M | 21.61M |
| CommonStockIssuance | 3.37M | 0.00 | 17.22M | 21.61M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | 11.67K | -584.16K | 2.19M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 11.67K | -584.16K | 2.19M |
| NetBusinessPurchaseAndSale | 0.00 | 3.06M | ||
| SaleOfBusiness | 0.00 | 3.06M | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -675.00K | ||
| PurchaseOfIntangibles | 0.00 | -675.00K | ||
| NetPPEPurchaseAndSale | 0.00 | 11.67K | -584.16K | -189.72K |
| SaleOfPPE | 0.00 | 16.85K | 0.00 | |
| PurchaseOfPPE | 0.00 | -5.18K | -584.16K | -189.72K |
| OperatingCashFlow | -7.73M | -14.09M | -17.15M | -11.46M |
| CashFlowFromContinuingOperatingActivities | -7.73M | -14.09M | -17.15M | -11.46M |
| ChangeInWorkingCapital | -423.24K | -174.75K | -217.66K | 1.19M |
| ChangeInOtherWorkingCapital | -64.05K | -107.29K | ||
| ChangeInOtherCurrentLiabilities | -107.29K | -24.97K | ||
| ChangeInPayablesAndAccruedExpense | -601.74K | -103.85K | 263.69K | 383.20K |
| ChangeInPayable | -601.74K | -103.85K | ||
| ChangeInAccountPayable | -834.63K | -103.85K | ||
| ChangeInPrepaidAssets | 178.50K | -6.86K | -374.06K | 826.84K |
| OtherNonCashItems | 418.20K | 1.85M | 1.16M | |
| StockBasedCompensation | 1.56M | 2.15M | 2.62M | 12.60M |
| AssetImpairmentCharge | 0.00 | 7.45M | 38.68M | |
| DeferredTax | 0.00 | -1.50M | -7.45M | |
| DeferredIncomeTax | 0.00 | -1.50M | -7.45M | |
| DepreciationAmortizationDepletion | 337.49K | 408.03K | 435.20K | 681.61K |
| DepreciationAndAmortization | 337.49K | 408.03K | 435.20K | 681.61K |
| AmortizationCashFlow | 168.75K | 168.75K | 168.75K | 643.33K |
| AmortizationOfIntangibles | 168.75K | 168.75K | 168.75K | 643.33K |
| Depreciation | 168.74K | 239.28K | 266.45K | 38.28K |
| OperatingGainsLosses | -45.99K | -1.03M | -7.46M | -9.33M |
| GainLossOnInvestmentSecurities | -45.99K | -1.03M | -7.46M | -9.33M |
| GainLossOnSaleOfPPE | 0.00 | -4.21K | 0.00 | |
| NetIncomeFromContinuingOperations | -9.57M | -17.29M | -18.47M | -48.98M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ENVB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|